Janux Therapeutics, Inc. (JANX)
18.93
+0.04
(+0.21%)
USD |
NASDAQ |
Aug 27, 09:48
Janux Therapeutics Max Drawdown (5Y) : 83.14% for July 31, 2026
Max Drawdown (5Y) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| July 31, 2026 | 83.14% |
| June 30, 2026 | 83.14% |
| May 31, 2026 | 83.14% |
| April 30, 2026 | 83.14% |
| March 31, 2026 | 83.14% |
| February 28, 2026 | 83.14% |
| January 31, 2026 | 83.14% |
| Date | Value |
|---|---|
| December 31, 2025 | 83.14% |
| November 30, 2025 | 83.14% |
| October 31, 2025 | 83.14% |
| September 30, 2025 | 83.14% |
| August 31, 2025 | 83.14% |
| July 31, 2025 | 83.14% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| MacroGenics, Inc. | 97.02% |
| Agenus, Inc. | 98.84% |
| Amgen, Inc. | 24.86% |
| Anika Therapeutics, Inc. | 83.15% |
| BioCryst Pharmaceuticals, Inc. | 79.10% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -40.81 |
| Beta (5Y) | 2.505 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 168.1% |
| Historical Sharpe Ratio (5Y) | -0.1056 |
| Historical Sortino (5Y) | -0.456 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 30.83% |